BOCH
MPLT

Blue Owl Capital Holdings’s MapLight Therapeutics MPLT Stock Holding History

Blue Owl Capital Holdings’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.5M Buy
1,005,929
+678,871
+208% +$12.1M 5.49% 7
2025
Q4 		$5.74M Buy
+327,058
New +$5.48M 1.77% 17

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Blue Owl Capital Holdings's MPLT Position: Q1 2026 in Review

Blue Owl Capital Holdings increased its MapLight Therapeutics (MPLT) stake by 208% in Q1 2026, buying an estimated $12.1M and bringing the position to 1,005,929 shares worth $20.5M. The position accounts for 5.49% of the portfolio, ranked #7.

Blue Owl Capital Holdings first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Blue Owl Capital Holdings held 1,005,929 shares of MapLight Therapeutics worth $20.5M as of Q1 2026.
  • Blue Owl Capital Holdings bought 678,871 MapLight Therapeutics shares in Q1 2026, an estimated $12.1M.
  • MapLight Therapeutics made up 5.49% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #7 holding.
  • Blue Owl Capital Holdings first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.